Searched for
PHRMA
Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its boardAnthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...- Trump unveils 100% tariff on some patented drugs on 'Liberation Day' anniversaryPresident Donald Trump has signed an executive order introducing significant pharmaceutical tariffs. Companies failing to strike pricing de...
- Tariff therapy: Trump nudges pharma cos to make drugs in US or face 100% tariffAmerica is set to impose hefty 100% tariffs on imported medicines. This move targets drug companies that do not agree to government pricing...
- Stock market update: Dilip Buildcon plunges 17% despite a jump in Q4 profitAround 11:45 am, shares of the company were trading at Rs 810.45 apiece, down 11.38 per cent, on the BSE.
- Drug MNCs lobby against price cuts of stents & knee implantsIn the last year India’s drug regulator has slashed prices of stents and knee implants by over 70% using an emergency provision in the drug...
- US pharma sector demands keeping India in patent violator listPhRMA in a submission requested US Trade Representative (USTR) to continue to keep India on the Priority Watch List in the 2017 Special 301...
- US pharma sector welcomes India's intellectual property policyThe US pharma sector has welcomed India's recent moves on intellectual property, including bringing out a draft policy and sustained engage...
- Big Pharma groupings urges US to ask India to change its IPR policiesIPR issues, especially over drugs, have long been a sticky point in India-US bilateral relations which both countries are now trying to res...
- Foreign drug makers urge government to review IPR think tankA similar point has also been raised by the US biotech groupings PhRMA and BIO in their submissions to the US Trade Representative's office.
- Incoming Narendra Modi government represents opportunity to US business: PhRMAIncoming Modi-led govt represents an 'excellent opportunity' for American industries to strengthen & rekindle their relationships with Indi...
- India’s IPR decisions have targeted the pharma sector the most: John J Castellani, PhRMA"To truly improve access to medicines in India, we need to continue to work together to advance sustainable policy solutions to healthcare ...
- India's IPR decisions have hit pharma sector the most, says John J Castellani, CEO, Pharmaceutical Research and Manufacturers of AmericaThe current system for intellectual property protection provides the necessary incentives for innovators in all fields of technology to dev...
- IP environment deteriorating in India: US pharma industryUS pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights are unr...
- Boeing, Pfizer, Dow among US entities lobbying on India issuesTogether, these companies and industry bodies have so far disclosed having spent more than $13 mn on their lobbying activities during the Q...
- US industry reviewing Supreme Court decision on NovartisUSIBC expressed its unease over SC on denying a patent on Glivec and said that this would impact innovation and investment climate in India.
- PhRMA to contribute USD 50,000 in PolioPlus programme in India"PhRMA has pledged to contribute USD 50,000 for 2013 for Rotary International's PolioPlus programme in India," PhRMA AVP Intl said.
- Indian cos will get to sell biosimilars in US market earlierDrugmakers are set to gain with US’ plan to reduce data exclusivity period to 7 years from 12 years.
- American lobby against plan for cheaper drugsThe lobbying body of American drugmakers has opposed the Indian government’s proposal to allow local drugmakers to make low-cost version of...
- Heavy lobbying by MNCs stalls US move to make drugs cheaperLegislation aimed at speeding the availability of cheaper generic drugs in the US has stalled in Congress in the face of major lobbying by ...
- Indian pharma majors back drug data exclusivity planThe tussle over the exclusive rights of the elaborate and costly data generated to support a new drug’s marketing application no longer see...
Load More
